Aptahem AB (XSAT:APTA) 12-1 Month Momentum %: -59.68% (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:APTA Aptahem AB XSAT:APTA
29 GF Score
Price kr0.38
! 1 Warning Sign
View Full Analysis

What is Aptahem AB 12-1 Month Momentum %?

Aptahem AB XSAT:APTA +21.41% 29 12-1 Month Momentum % is -59.68% as of Sep. 20, 2026. GuruFocus rates XSAT:APTA with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,352 Biotechnology companies, Aptahem AB ranks worse than 83.73% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-20), Aptahem AB's 12-1 Month Momentum % is -59.68%.

The industry rank for Aptahem AB's 12-1 Month Momentum % or its related term are showing as below:

XSAT:APTA's 12-1 Month Momentum % is ranked worse than
83.73% of 1352 companies
in the Biotechnology industry
Industry Median: -20.52 vs XSAT:APTA: -59.68

Aptahem AB  (XSAT:APTA) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Aptahem AB 12-1 Month Momentum % Related Terms

XSAT:APTA vs VRTX, REGN, MRNA: 12-1 Month Momentum % Comparison

For the Biotechnology subindustry, Aptahem AB's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptahem AB 12-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptahem AB's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Aptahem AB's 12-1 Month Momentum % falls into.


XSAT:APTA
29GF Score
Aptahem AB XSAT:APTA
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptahem AB  (XSAT:APTA) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of -59.68% mean?
Aptahem AB (XSAT:APTA) has a 12-1 Month Momentum % of -59.68% as of Sep. 20, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Aptahem AB and its competitors. According to the industry distribution chart, Aptahem AB ranks #1132 out of 1352 companies in the Biotechnology industry, placing it in the top 83.7%.
Is Aptahem AB's 12-1 Month Momentum % too high?
Aptahem AB's current 12-1 Month Momentum % is -59.68%. Based on the distribution chart, Aptahem AB ranks #1132 out of 1352 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aptahem AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptahem AB's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aptahem AB ranks #1132 out of 1352 companies for 12-1 Month Momentum %. This places Aptahem AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Aptahem AB and its competitors. Aptahem AB's current 12-1 Month Momentum % is -59.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptahem AB stock overvalued right now?
Aptahem AB (XSAT:APTA) has a current 12-1 Month Momentum % of -59.68%. The current 12-1 Month Momentum % is -59.68%. Aptahem AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Aptahem AB (XSAT:APTA), the current 12-1 Month Momentum % is -59.68% as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptahem AB Business Description

Address Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
29GF Score

Get the complete analysis for XSAT:APTA

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.38
Price